DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Inclusion Criteria:

- 18 years of age at time of signing informed consent

- Histology-confirmed aggressive B-cell Non-Hodgkin lymphoma

- De novo diffuse large B-cell lymphoma (including all subtypes such as primary
mediastinal B-cell lymphoma and T-cell rich B-cell lymphoma). According to the
2008 WHO Classification of Hematopoietic and Lymphoid Tumors. These would include
double or triple-hit diffuse large B-cell lymphomas with MYC/BCL2 and/or BCL6
gene rearrangements. These cases may be classified as high grade B-cell lymphomas
according to the 2017 revision of the WHO Classification of Hematopoietic and
Lymphoid Tumors.

- Recipient of frontline multi-agent chemotherapy (for example, RCHOP, dose
adjusted-REPOCH, RCHOP/RICE, RCHOP+investigational agent, etc). Eligible patients will
have recently received (≤ 4 months from end of treatment assessment), be actively
receiving, or planned to receive frontline chemotherapy in near future (within 3
months of signing consent). A frontline therapy program can include different
sequential phases of treatment, including high-dose therapy and autologous stem cell
transplantation.

- Required pre-treatment test specimen from bone marrow, blood, lymph node, or alternate
site to identify tumor-specific clonotype.

- Ability to adhere to the study visit schedule and all the protocol requirements,
including surveillance imaging and MRD test specimen collection at specified time
points.

Exclusion Criteria:

- Patients receiving 2nd or greater line of therapy.